New medications for rheumatoid arthritis; improved treatment options place new demands on health care organizations;Nya läkemedel mot reumatoid artrit: Förbättrade behandlingsmöjligheter ställer nya krav på sjukvårdsorganisationen

Lakartidningen

Volumn 97, Issue 48, 2000, Pages 5628-5632

  Klareskog, Lars ^a   Hafström, Ingiäld ^b   Saxne, Tore ^c   Hedin, Per Johan ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Reumatologiska Kliniken   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d FALUN HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT;

COST OF ILLNESS; DRUG COMBINATION; ECONOMICS; HEALTH CARE POLICY; HUMAN; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; STANDARD; SWEDEN;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; DRUG THERAPY, COMBINATION; HEALTH POLICY; HUMANS; PRACTICE GUIDELINES; RHEUMATOLOGY; SWEDEN;

EID: 0034731097     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Leeuwen MA, van Risjwijk MH, van der Heijde DM, Meerman TE, van Riel PL, Houtman PM et al. The acute phase response in relation to radiographic progression in early rheumatoid arthritis; a prospective study during the first 3 years of dis-ease. Br J Rheumatol 1993; 32 suppl 3: 26-30.
2. Fex E, Larsson BM, Nived K. Effect of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol 1998; 25: 44-50.
3. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.
4. Fries JF, Williams CA, Morfeld D, Singh G, Sibley JT. Reduction in longterm disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996; 39: 616-22.
5. Furst DE, Breedveld FC, Burmester GR, Crofford L, Emery P, Feldman M et al. Access to disease modifying treatments for rheumatoid arthritis patients. Consensus statement. Ann Rheum Dis 1999; 58: suppl 1: 1129-30.
6. Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR et al. Consensus statement on the initiation and continuation of TNF blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000; 59: 504-5.
7. Möttonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial Group. Lancet 1999; 353: 1568-73.
8. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-91.
9. van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998; 5: 277-92.
10. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al. European leflunomide study group. Efficacy and saftey of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259-66.
11. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial: Attract study group. Lancet 1999; 354: 1932-9.
12. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
13. Lipsky P, van der Heijde D, St Clair W, Smolen J, Furst D, Kalden J et al. 102-week clinical and radiologic results from the ATTRACT trial: a two year, randomized, controlled, phase three trial of infliximab (Remicade) in patients with active RA despite methotrexate. Arthritis Rheum 2000; 43 suppl 9: 1216.
14. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 2106-11.
15. Blomqvist P, Feltelius N, Ekbom A, Klareskog L. Drug prescriptions, costs, and adverse drug reactions. J Rheumatol 2000; 27: 1171-7.